Astrazeneca (AZN) Income from Non-Controlling Interests (2009 - 2026)

Astrazeneca (AZN) has reported Income from Non-Controlling Interests for 18 consecutive years, with $1.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income from Non-Controlling Interests fell 85.71% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $10.0 million (down 9.09% YoY), while the FY2025 annual figure was $8.0 million, up 33.33% from the prior year.
• Income from Non-Controlling Interests came in at $1.0 million for Q1 2026 at Astrazeneca, down from $9.0 million in the prior quarter.
• The five-year high for Income from Non-Controlling Interests was $9.0 million in Q4 2025, with the low at -$2.0 million in Q2 2025.
• Average Income from Non-Controlling Interests over 5 years is $2.1 million, with a median of $1.5 million recorded in 2022.
• The largest YoY upside for Income from Non-Controlling Interests was 1000.0% in 2025 against a maximum downside of 300.0% in 2025.
• Year by year, Income from Non-Controlling Interests stood at $1.0 million in 2022, then plunged by 200.0% to -$1.0 million in 2023, then changed by 0.0% to -$1.0 million in 2024, then surged by 1000.0% to $9.0 million in 2025, then slumped by 88.89% to $1.0 million in 2026.
• According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $1.0 million, $9.0 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.